The Class III pathway in orthopedics brutally slow, opaque, and unpredictable.
If you ask the industry, we point to the data. We argue over sample sizes, mechanical testing protocols, and clinical trial endpoints. We pretend the bottleneck is purely scientific.
It isn’t. Not even close.
The real reason the Class III pathway feels like a black hole is far simpler, far more human, and infinitely harder to fix: asymmetric behavioral psychology.
We keep expecting a bureaucratic system to act like an innovation engine, completely ignoring the fact that the human beings sitting across the table from us are operating under a textbook case of career survival.
The Bureaucratic Math: Type I vs. Type II Errors
Consider the brutal reality of an FDA reviewer’s career architecture:
The Cost of a Type I Error (False Positive): If a reviewer approves a novel total joint or spinal scaffold that later catastrophically fails in thousands of patients, their name is on the evening news. Their career is toast. Their inbox fills with congressional subpoenas and plaintiff depositions.
The Cost of a Type II Error (False Negative): If a reviewer rejects or indefinitely delays a breakthrough device that wou...
